Literature DB >> 10229659

Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids.

T A Brighton1, Y P Dai, P J Hogg, C N Chesterman.   

Abstract

Considerable interest is currently focused on the interactions of beta-2 glycoprotein I (beta2GPI) and anti-phospholipid antibodies with anionic phospholipids in an attempt to understand the association between these antibodies and clinical diseases such as thrombosis. The interactions of beta2GPI and anionic phospholipids have only been characterized partially, and the physiological role of this glycoprotein remains uncertain. In this study we have explored in detail the physical and phospholipid-binding characteristics of a number of beta2GPI preparations. We have found (i) that perchloric acid-purification methods are damaging to beta2GPI during purification, (ii) that the dissociation constants of the various preparations for phosphatidylserine vary between 0. 1-2 microM and are considerably weaker than previously reported, (iii) that considerable differences in affinity of the various beta2GPI preparations for anionic phospholipids are obtained when comparing anionic phospholipids immobilized to a solid-phase versus phospholipid assembled in unilamellar vesicles, (iv) that the integrity of the fifth domain of beta2GPI is important for binding immobilized anionic phospholipid but not especially important in binding vesicular anionic phospholipid, and (v) that beta2GPI preparations with differing isoelectric species content bind anionic phospholipids differently, suggesting that varying glycosylation and/or protein polymorphisms impact upon phospholipid binding. These results highlight the importance of assessing the determinants of the interaction of beta2GPI with anionic phospholipids assembled in unilamellar vesicles.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229659      PMCID: PMC1220222     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Molecular basis of the apolipoprotein H (beta 2-glycoprotein I) protein polymorphism.

Authors:  D K Sanghera; T Kristensen; R F Hamman; M I Kamboh
Journal:  Hum Genet       Date:  1997-07       Impact factor: 4.132

2.  Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (beta 2-glycoprotein I).

Authors:  M I Kamboh; R E Ferrell; B Sepehrnia
Journal:  Am J Hum Genet       Date:  1988-03       Impact factor: 11.025

3.  Characterization of subfractions of beta 2-glycoprotein I: evidence for sialic acid microheterogeneity.

Authors:  I Schousboe
Journal:  Int J Biochem       Date:  1983

4.  beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.

Authors:  I Schousboe
Journal:  Blood       Date:  1985-11       Impact factor: 22.113

5.  beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles.

Authors:  H Wurm
Journal:  Int J Biochem       Date:  1984

6.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

Authors:  J Nimpf; E M Bevers; P H Bomans; U Till; H Wurm; G M Kostner; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1986-10-29

7.  Complete amino acid sequence of human plasma beta 2-glycoprotein I.

Authors:  J Lozier; N Takahashi; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Genetic variations of human serum beta 2-glycoprotein I demonstrated by isoelectric focusing.

Authors:  A Richter; H Cleve
Journal:  Electrophoresis       Date:  1988-07       Impact factor: 3.535

9.  Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system.

Authors:  M Igarashi; E Matsuura; Y Igarashi; H Nagae; K Ichikawa; D A Triplett; T Koike
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

10.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside.

Authors:  L T Mimms; G Zampighi; Y Nozaki; C Tanford; J A Reynolds
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

View more
  6 in total

1.  Biotinylation of glycan chains in beta2 glycoprotein I induces dimerization of the molecule and its detection by the human autoimmune anti-cardiolipin antibody EY2C9.

Authors:  Arnaud Dupuy D'Angeac; Ilias Stefas; Hubert Graafland; Frédéric De Lamotte; Marcel Rucheton; Caroline Palais; Anna-Karin Eriksson; Priscille Bosc; Caroline Rosé; Robert Chicheportiche
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Quantitative determination of the binding of beta2-glycoprotein I and prothrombin to phosphatidylserine-exposing blood platelets.

Authors:  Edouard M Bevers; Marie P Janssen; Paul Comfurius; Krishnakumar Balasubramanian; Alan J Schroit; Robert F A Zwaal; George M Willems
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

3.  Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.

Authors:  Omid Safa; Charles T Esmon; Naomi L Esmon
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

Review 4.  Plasmodium's fight for survival: escaping elimination while acquiring nutrients.

Authors:  Erin A Schroeder; Michael E Chirgwin; Emily R Derbyshire
Journal:  Trends Parasitol       Date:  2022-05-06

5.  Optimization of unnicked β2-glycoprotein I and high avidity anti-β2-glycoprotein I antibodies isolation.

Authors:  Andrej Artenjak; Adrijana Leonardi; Igor Križaj; Aleš Ambrožič; Snezna Sodin-Semrl; Borut Božič; Saša Cučnik
Journal:  J Immunol Res       Date:  2014-01-23       Impact factor: 4.818

6.  Diagnosis of antiphospholipid syndrome in routine clinical practice.

Authors:  C Gardiner; J Hills; S J Machin; H Cohen
Journal:  Lupus       Date:  2012-09-17       Impact factor: 2.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.